Il closing è previsto entro la fine dell`anno. Il valore dell’operazione non è stato comunicato.
The pharmaceutical division of Bracco, for which a turnover of around 80 million euro is expected in 2016 (equal to 6% of the group's turnover), operates exclusively on the Italian market with a product portfolio that includes both ethical drugs belonging to the main therapeutic sectors such as the gastrointestinal, neurological, endocrinological and cardiovascular ones, as well as over-the-counter drugs and supplements, with some well-known brands.